Segment Information - Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Net sales	$ 3,776	$ 3,197	$ 9,711	$ 5,857
Gross profit	597	1,757	2,506	3,175
Direct expenses	41,877	51,774	78,445	76,390
Segment contribution	(41,280)	(50,017)	(75,939)	(73,215)
Indirect expenses	(45,455)	10,594	(38,500)	31,791
Income (loss) from operations	4,175	(60,611)	(37,439)	(105,006)
Components of other
Change in fair value of contingent consideration liability	(45,047)	10,048	(40,198)	30,704
Change in fair value of contingent stock consideration			611
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	24,820	22,105	46,033	38,392
Segment contribution	(24,820)	(22,105)	(46,033)	(38,392)
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,373	1,597	2,656	2,861
Gross profit	108	1,029	443	1,569
Direct expenses	256	742	882	994
Segment contribution	(148)	287	(439)	575
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	2,403	1,600	7,055	2,996
Gross profit	489	728	2,063	1,606
Direct expenses	3,179	2,150	4,638	4,164
Segment contribution	(2,690)	(1,422)	(2,575)	(2,558)
Other
Segment Reporting Information [Line Items]
Direct expenses	13,622	26,777	26,892	32,840
Segment contribution	(13,622)	(26,777)	(26,892)	(32,840)
Indirect expenses	(45,455)	10,594	(38,500)	31,791
Components of other
Change in fair value of contingent consideration liability	(45,047)	10,048	(40,198)	30,704
Change in fair value of contingent stock consideration	(954)		611
Amortization	546	546	1,087	1,087
Total other	$ (45,455)	$ 10,594	$ (38,500)	$ 31,791